The High-Stakes Gamble: BioNTech’s Bold Leap Beyond the COVID-19 Vaccine
BioNTech is transitioning from COVID-19 vaccines to cancer therapies, leveraging mRNA technology. Recent financial results show a decline in profits, but still exceeded market expectations. BioNTech plans to invest €2.8 billion in research and development for cancer treatment innovations. Promising developments include mRNA therapeutics for bladder and colorectal cancer, especially BNT327. BioNTech expects market approval […]
Continue Reading